研究活動
Research Activities

研究活動
Research Activities

Home › 研究活動 › 主任研究者 › 金子 新 教授

主任研究者
Principal Investigators

増殖分化機構研究部門 金子 新 教授

発表論文

Kurihara S, Ishikawa A, Kaneko S

Genome edits on iPSC purposing enhancement of induced CD8 Killer T cell function for regenerative immunotherapy Inflammation and Regeneration, 2024 Apr 18;44(1):20

Gravina A, Tediashvili G, Zheng Y, Iwabuchi KA, Peyrot SM, Roodsari SZ, Gargiulo L, Kaneko S, Osawa M, Schrepfer S, Deuse T

Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity Cell Stem Cell, 2023 Nov 30(11):1538-1578.e4

Takayanagi SI, Wang B, Hasegawa S, Nishikawa S, Fukumoto K, Nakano K, Chuganji S, Kato Y, Kamibayashi S, Minagawa A, Kunisato A, Nozawa H, Kaneko S

Mini-TCRs: Truncated T cell receptors to generate T cells from induced pluripotent stem cells Molecular Therapy - Methods & Clinical Development, 2023 Sep 31:101109

Flahou C, Morishima T, Higashi N, Hayashi Y, Xu H, Wang B, Zhang C, Ninomiya A, Qiu WY, Yuzuriha A, Suzuki D, Nakamura S, Manz M, Kaneko S, Hotta A, Takizawa H, Eto K, Sugimoto N

Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I- edited iPSC-derived cells Biochemical and Biophysical Research Communications, 2023 Apr 662:76-83

Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S

Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nature Biomedical Engineering, 2023 Jan;7(1):24-37.

Ishikawa A, Waseda M, Ishii T,Kaneko K. M, Kato Y, Kaneko S.

Improved anti-solid tumor response by humanized anti-podoplanin chimeric antigen receptor transduced human cytotoxic T cells in an animal model. Genes to Cells, 2022 Sep;27(9):549-558.

Yohei Kawai, Ai Kawana-Tachikawa, Shuichi Kitayama, Tatsuki Ueda, Shoji Miki, Akira Watanabe, Shin Kaneko

Generation of highly proliferative rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy. Mol Ther., 2021 Oct 6;29(10):3027-3041. doi: 10.1016/j.ymthe.2021.05.016. Epub 2021 May 21.

Takeshi Ito, Yohei Kawai, Yutaka Yasui, Shoichi Iriguchi, Atsutaka Minagawa, Tomoko Ishii, Hiroyuki Miyoshi, M. Mark Taketo, Kenji Kawada, Kazutaka Obama, Yoshiharu Sakai, Shin Kaneko

The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-derived iPS cells. Commun Biol., 2021 Jun 7;4(1):694. doi: 10.1038/s42003-021-02195-x.

Bo Wang, Shoichi Iriguchi, Masazumi Waseda, Norihiro Ueda, Tatsuki Ueda, Huaigeng Xu, Atsutaka Minagawa, Akihiro Ishikawa, Hisashi Yano, Tomoko Ishi, Ryoji Ito, Motohito Goto, Riichi Takahashi,Yasushi Uemura, Akitsu Hotta, and Shin Kaneko

Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells Nature Biomedical Engineering, 2021 May;5(5):429-440.

Iwamoto Y, Seki Y, Taya K, Tanaka M, Iriguchi S, Miyake Y, Nakamura E. E, Miura T, Shioda T, Akari H, Takaori-Kondo A, Kaneko S.

Generation of macrophages with altered viral sensitivity from genomeedited rhesus macaque iPSCs to model human disease Molecular Therapy - Methods & Clinical Development, 21:262+273 (2021)

Mashima H, Zhang R, Kobayashi T, Tsukamoto H, Liu T, Iwama T, Hagiya Y, Yamamoto M, Fukushima S, Okada S, Idiris A, Kaneko S, Nakatsura T, Ohdan H, Uemura Y.

Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy. Molecular Therapy - Methods & Clinical Development, 21:171-179 (2021)

Ishigaki H, Pham VL, Terai J, Sasamura T, Nguyen CT, Ishida H, Okahara J, Kaneko S, Shiina T, Nakayama M, Itoh Y, Ogasawara K.

No Tumorigenicity of Allogeneic Induced Pluripotent Stem Cells in Major Histocompatibility Complex-matched Cynomolgus Macaques. Cell Transplant, 30:1-12 (2021)

Iriguchi s, Yasui Y, Kawai Y, Arima S, Kunitomo M, Sato T, Ueda T, Minagawa A, Mishima Y, Yanagawa N, Baba Y, Miyake Y, Nakayama K, Takiguchi M, Shinohara T, Nakatsura T, Yasukawa M, Kassai Y, Hayashi A, Kaneko S.

A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nature Communications, 12(1):430 (2021)

Kazuki Y, Uno N, Abe S, Kajitani N, Kazuki K, Yakura Y, Sawada C, Takata S, Sugawara M, Nagashima Y, Okada A, Hiratsuka M, Osaki M, Ferrari G, Tedesco FS, Nishikawa S, Fukumoto K, Takayanagi SI, Kunisato A, Kaneko S, Oshimura M, Tomizuka K.

Engineering of human induced pluripotent stem cells via human artificial chromosome vectors for cell therapy and disease modeling. Mol Ther Nucleic Acids, 23:629-639 (2020)

Koga K, Wang B, Kaneko S.

Current status and future perspectives of HLA-edited induced pluripotent stem cells. Inflammation and Regeneration, 40(23):40:23 (2020)

Ueda T, Kumagai A, Iriguchi S, Yasui Y, Miyasaka T, Nakagoshi K, Nakane K, Saito K, Takahashi M, Sasaki A, Yoshida S, Takasu N, Seno H, Uemura Y, Tamada K, Nakatsura T, Kaneko S.

Non‐clinical efficacy, safety, and stable clinical cell processing of iPSC‐derived anti‐GPC3 CAR‐expressing NK/ILC cells. Cancer Science, 111(5):1478-1490 (2020)

Zhang R, Kitayama S, Liu T, Ueda N, Tokumitsu Y, Mashima H, Ohdan H, Kaneko S, Uemura Y.

In Vitro Detection of Cellular Adjuvant Properties of Human Invariant Natural Killer T Cells. Methods Mol Biol., 2048:121-130 (2019)

Iriguchi S, Kaneko S.

In Vitro Differentiation of T Cells: From Nonhuman Primate-Induced Pluripotent Stem Cells Methods Mol Biol., 2048:93-106 (2019)

Ueda T, Kaneko S.

In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC. Methods Mol Biol., 2048:85-91 (2019)

Minagawa A, Kaneko S.

Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy. Methods Mol Biol., 2048:81-84 (2019)

Yasui Y, Hitoshi Y, Kaneko S.

In Vitro Differentiation of T Cell: From Human iPS Cells in Feeder-Free Condition. Methods Mol Biol., 2048:77-80 (2019)

Kawai Y, Kaneko S.

Redifferentiation of Adaptive Naïve-Like CTL from T-Cell-Derived iPSC. Methods Mol Biol., 2048:71-75 (2019)

Iriguchi S, Kaneko S.

In Vitro Differentiation of T Cells: From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells. Methods Mol Biol., 2048:59-70 (2019)

Radulovic V, van der Garde M, Koide S, Sigurdsson V, Lang S, Kaneko S, Miharada K.

Junctional Adhesion Molecule 2 Represents a Subset of Hematopoietic Stem Cells with Enhanced Potential for T Lymphopoiesis. Cell Report, 27(10):2826-2836.e5. (2019)

Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, Ueda T, Gee P, Nishikawa M, Nomura M, Kitaoka F, Takahashi T, Okita K, Yoshida Y, Kaneko S, Hotta A.

Targeted Disruption of HLA genes via CRISPR-Cas9 generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 24(4):566-578.E7, April 4, 2019 (Published: March 7, 2019)

Torisawa Y, Mishima Y, Kaneko S.

Developing thymus-on-a-chip and cancer-on-a-chip for cancer immunotherapy. Impact. 29(2):33-35(3), 2019. doi: 10.1016/j.stem.2019.02.00.

Iriguchi S, Kaneko S.

Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy. Cancer Science. 110(1):16-22, 2018.

Minagawa A, Yoshikawa T, YasukawaT, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S.

Enhancing T cell Receptor Stability in Rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell. 23(6):850-858, 2018. doi: 10.1016/j.stem.2018.10.005.

Higaki K, Hirao M, Kawana-Tachikawa A, Iriguchi S, Kumagai A, Ueda N, Bo W, Kamibayashi S,  Watanabe A, Nakauchi H, Suzuki K, Kaneko S.

Generation of HIV-Resistant Macrophages from iPSCs by Using Transcriptional Gene Silencing and Promoter-Targeted RNA. Molecular Therapy Nucleic Acids. 12(7):793-804, 2018. doi: 10.1016/j.omtn.2018.07.017.

Lee S, Huh JY, Turner D, Lee S, Robinson J, Stein J, Shim SH, Hong CP, Kang MS, Nakagawa M, Kaneko S, Rao M, Kurtz A, Stacey G, Marsh S, Turner M, Song J.

Repurposing the Cord Blood Bank for Haplobanking of HLA-Homozygous iPSCs and Their Usefulness to Multiple Populations. Stem Cells. 36(10):1552-1566,2018. doi: 10.1002/stem.2865

Ueda N, Uemura Y, Zhang R, Kitayama S, Iriguchi S, Kawai Y, Yasui Y, Tatsumi M, Liu TY, Mizoro Y, Okada C, Watanabe A, Nakanishi M, Senju S, Nishimura Y, Kuzushima K, Kiyoi H, Naoe T, and Kaneko S.

Regeneration of TCR expressing Innate Lymphoid helper cells that induces cytotoxic T cell-mediated anti-leukemic immunity in HLA Class II and bcr-abl peptide restriction. Stem Cell Reports. 10(6):1935-1946, 2018. doi: 10.1016/j.stemcr.2018.04.025.

Oshima K, Saiki N, Tanaka M, Imamura H, Niwa A, Tanimura A, Nagahashi A, Hirayama A, Okita K, Hotta A, Kitayama S, Osawa M, Kaneko S, Watanabe A, Asaka I, Fujibuchi W, Imai K, Yabe H, Kamachi Y, Hara J, Kojima S, Tomita M, Soga T, Noma T, Nonoyama S, Nakahata T, Saito MK.

Human AK2 links intracellular bioenergetic redistribution to the fate of hematopoietic progenitors. Biochem Biophys Res Commun. 2018, 497(2), 719-725, doi: 10.1016/j.bbrc.2018.02.139.

Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y.

BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells. Cell Mol Immunol. 2016 May 16.

Kaneko S.

In Vitro Generation of Antigen-Specific T Cells from Induced Pluripotent Stem Cells of Antigen-Specific T Cell Origin. Methods Mol Biol. 01 April 2016.

Sugai S, Yoshikawa T, Iwama T, Tsuchiya N, Ueda N, Fujinami N, Shimomura M, Zhang R, Kaneko S, Uemura Y, Nakatsura T.

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate. Int J Oncol. 2016 May;48(5):1794-804.

Kitayama S, Zhang R, Tian-Yi Liu, Ueda N, Iriguchi S, Yasui Y, Kawai Y, Tatsumi M, Hirai N, Mizoro Y, Iwama T, Watanabe A, Nakanishi M, Kuzushima K, Uemura Y, and Kaneko S.

Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Va24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells. Stem Cell Reports. 2016 Feb 9;6(2):213-227.

Karagiannis P, Iriguchi S, Kaneko S.

Reprogramming away from the exhausted T cell state. Semin Immunol. 2015 Nov 14.

Iriguchi S, Kikuchi N, Kaneko S, Noguchi E, Morishima Y, Matsuyama M, Yoh K, Takahashi S, Nakauchi H, Ishii Y.

T cell-restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of lung macrophages in the lung. Blood. 2015 Jan 8;125(2):370-82. Epub 2014 Oct 27.

Mianagawa A, Kaneko S.

Rise of iPSCs as a cell source for adoptive immunotherapy. Human Cell. 2014 Apr;27(2):47-50.

Hirata S, Takayama N, Jono-Ohnishi R, Endo H, Nakamura S, Dohda T, Nishi M, Hamazaki Y, Ishii E, Kaneko S, Otsu M, Nakauchi H, Kunishima S, Eto K.

Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling. J Clin Invest. 2013 Sep 3;123(9):3802-14.

Kaneko S, Yamanaka S.

To be immunogenic, or not to be: that's the iPSC question. Cell Stem Cell. 2013 Apr 4;12(4):385-6.

Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Gotoh H, Zhu D, Nakayama K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H.

Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013 Jan 3;12(1):114-26.

Bondanza A, Hambach L, Aghai Z, Nijmeijer B, Kaneko S, Mastaglio S, Radrizzani M, Fleischhauer K, Ciceri F, Bordignon C, Bonini C, and Goulmy E.

IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. Blood. 117:6469-78, (2011)

Shimizu T, Sano S, Takayama N, Kaneko S(corresponding author), Eto K, Takeuchi Y, Nakauchi H.

Constitutive STAT5A activation enables erythropoiesis from human embryonic stem cell-derived primitive hematopoietic cells in the absence of erythropoietin. Kitasato Med. J. 41:42-49, (2011)

Kaneko S, Otsu M, and Nakauchi H.

Reprogramming of adult hematopoietic cells. Curr. Opinion. in Hematol. 17:271-5, (2010)

Kaneko S, Mastaglio S, Bondanza A, Ponzoni M, Sanvito F, Aldrighetti L, Radrizzani M, La Seta-Catamancio S, Provasi E, Mondino A, Nagasawa T, Fleischhauer K, Russo V, Traversari C, Ciceri F, Bordignon C, and Bonini C.

IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood. 113: 1006-15, (2009)

Sanuki S, Hamanaka S, Kaneko S, Otsu M, Karasawa S, Miyawaki A, Nakauchi H, Nagasawa T, and Onodera M.

A new red fluorescent protein that allows efficient marking of murine hematopoietic stem cells. J Gene Med 10: 9 65-71, (2008)

Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F and Bordignon C.

The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 15:1248-52, (2007)

Machino T, Okoshi Y, Kaneko S, Obara N, Mukai HY, Suzukawa K, Hasegawa Y, Yamashita Y, Mori N, Kojima H, and Nagasawa T.

Hepatosplenic alphabeta T-cell lymphoma successfully treated with allogeneic bone marrow transplantation. Bone Marrow Transplant 39:513-4, (2007)

Muto H, Kaneko S, Machino T, Okoshi Y, Mukai HY, Suzukawa K, Hasegawa Y, Imagawa S, Kojima H, Ishii Y, Hitomi S and Nagasawa T.

Quinupristin/dalfopristin and voriconazole controlled Staphylococcus epidermidis pneumonia and chronic necrotizing aspergillosis in a patient with severe lung degradation consequent to multiple treatments for Hodgkin’s lymphoma. J Infect Chemother 12:391-5, (2006)

Kaneko S, Nagasawa T, Nakauchi H and Onodera M.

An in vivo assay for retrovirally transduced human peripheral T lymphocytes using non-obese diabetic/ severe combined immunodeficiency mice. Exp. Hematol 33:35-41, (2005)

Shinagawa A, Kojima H, Berndt MC, Kaneko S, Suzukawa K, Hasegawa Y, Shigeta O, and Nagasawa T.

Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost. 93:889-96, (2005)

Kojima H, Hasegawa Y, Suzukawa K, Mukai HY, Kaneko S, Kobayashi T, Kamoshita M, Shinagawa A, Komeno T, Komatsu T, Mitsuhashi S, Kawachi Y, Yamashita Y, Mori N, and Nagasawa T.

Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification. Leuk Res. 28:1287-92, (2004)

Yoshida C, Kojima H, Ishigaki T, Katsura Y, Kaneko S, Suzukawa K, Hasegawa Y, Kawachi Y, Otsuka F, and Nagasawa T.

Association of pyoderma gangrenosum and sterile osteomyelitis in a patient having myelodysplastic syndrome with der(1;7)(q10;q10). Eur J Haematol. 72:149-53, (2004)

Suzuki A, Obi K, Urabe T, Hayakawa H, Yamada M, Kaneko S, Onodera M, Mizuno Y, and Mochizuki H.

Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein. J Neurochem. 82: 953-60, (2002)

Osawa M, Yamaguchi T, Nakamura Y, Kaneko S, Onodera M, Sawada K, Jegalian A, Wu H, Nakauchi H, and Iwama A.

Erythroid expansion mediated by the Gfi-1B zinc finger protein: role in normal hematopoiesis. Blood 100:2769-2777. (2002)

Iwama A, Osawa M, Hirasawa R, Uchiyama N, Kaneko S, Onodera M, Shibuya K, Shibuya A, Vinson C, Tenen DG, and Nakauchi H.

Reciprocal roles for CCAAT/enhancer binding protein (C/EBP) and PU.1 transcription factors in Langerhans cell commitment. J Exp Med 195:547-558, (2002)

Suzuki A, Zheng YY, Kaneko S, Onodera M, Fukao K, Nakauchi H, and Taniguchi H.

Clonal identification and Characterization of self-renewing pluripotent stem cells in the developing liver. J Cell Biol 156:173-184, (2002)

Kaneko S, Onodera M, Fujiki Y, Nagasawa T, and Nakauchi H.

The simplified retroviral vector GCsap with murine stem cell virus long terminal repeat allows high and continued expression of enhanced green fluorescent protein by human hematopoietic progenitors engrafted in non-obese diabetic/severe combined immunodeficiency mice. Hum Gene Ther 12:35-44, (2001)

Yasukawa M, Hasegawa A, Sakai I, Ohminami H, Arai J, Kaneko S, Yakushijin Y, Maeyama K, Nakashima H, Arakaki R, and Fujita S.

Down-regulation of CXCR4 by human herpesvirus 6 (HHV-6) and HHV-7. J Immunol 162:5417-5422, (1999)

Ohminami H, Yasukawa M, Kaneko S, Yakushijin Y, Abe Y, Kasahara Y, Ishida Y, and Fujita S.

Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood 93:925-935, (1999)

Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, Miyakuni T, Nakao S, Kishi K, Kubonishi I, Dan K, and Fujita S.

CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 92:3355-3361, (1998)

Kaneko S, Nagata M, Takemura H, Yuhara T, Akama T, Suzuki H, Yamane K, and Kashiwagi H.

Gelatinous transformation of bone marrow with pancytopenia in an emaciated patient with systemic lupus erythematosus. Jpn J Rheumatol 8:167-173, (1998)
和文総説・著作物

泉 響介、石川 晃大、金子 新

ゲノム編集iPS細胞を用いたuniversal CAR-T/NK細胞のフロンティア 医学のあゆみ, 288(3):211-216

石黒義孝、金子新

5-6.がん免疫 細胞培養・組織培養の技術 第4版, 227-232.

柴田翔、金子新

iPS細胞を使用した免疫療法の開発 血液内科 85(6):883-888

早稲田真澄、金子新

人工胸腺オルガノイドからのCAR-T細胞の分化 実験医学・増刊 41(2):101-106

河合洋平、金子新

iPS細胞を用いたがん免疫療法について BIO EX-press

金子新

同種iPS細胞から誘導したCAR-T療法の開発 臨床血液 63(10):1454-1460

金子新

iPS細胞からのT細胞再生と同種CAR-T療法、TCR-T療法の開発 臨床血液 63(9)1279-1289

金子新

iPS細胞を用いた免疫療法 必修!腫瘍免疫学 113-116

岩本芳浩、金子新

iPS細胞とマクロファージ 実験医学 増刊 40(5):655-660

伊藤剛、金子新

iPS細胞のがん免疫療法への応用 腫瘍内科 29(2):188-193, 2022

入口翔一、金子新

iPS細胞を使った "off-the-shelf" CAR-T細胞の開発 Bio Clinica 36(12), 2021.

金子新

iPS細胞を用いたがんに対する免疫療法 別冊・医学のあゆみ 274(6), 609-612, 2021.

早稲田真澄、金子新

iPS細胞技術を用いたがん免疫療法 Bio Clinica, 34(1):25-29, 2019.

金子新

iPS細胞技術を応用したがん免疫療法
-幹細胞生物学、腫瘍免疫学、遺伝子治療学の融合が生み出しつつあるもの-
最新医学2018, 73(2), 92-97.

矢野寿、金子新

iPS細胞を用いた免疫細胞療法 臨床血液2018, 59(2), 225-230.

冨岡亮作、金子新

供給体制と臨床試験拠点病院 Clinical Neuroscience 2018, 36(3), 338-341.

入口翔一、金子新

ES細胞、iPS細胞ってどんな細胞ですか?主な違いは何ですか?
-ダイレクトリプログラミングを含めて-
小児内科 2017, 49(7), 918-921.

三嶋雄太、金子新

iPS細胞の応用研究 
-これまでの応用例と課題、最新の応用例
生物の科学「遺伝」 2017, 71(5), 425-430.

南川淳隆、金子新

ラボ必携 フローサイトメトリーQ&A
~正しいデータを出すための100箇条~
実験医学別冊2017, 278-279.

上田格弘、金子新

がん免疫療法 -がん完治に向けての新たな治療法の探索- 
Ⅲ.iPS細胞からの免疫細胞作製とがん免疫療法への応用
日本臨牀 75(2) 317-322, 2017

大迫洋平、金子新

再生医療・細胞治療のための細胞加工物評価技術 
第22章 臨床用原材料細胞のセルバンク
シーエムシー出版バイオテクノロジーシリーズ 229-239, 2016

吉田信介、金子新

iPS細胞ストック 臨床免疫・アレルギー科 2016-06;65(6):615-62

上田樹、金子新

多能性幹細胞のT細胞研究への応用 日本免疫学会会誌 2015;38(2):101-8

金子新

iPS細胞を用いた免疫細胞のin vitro再生 別冊「医学のあゆみ」iPS細胞研究最前線 2015

金子新

iPS細胞技術による腫瘍免疫・感染免疫の再生、増刊「実験医学 」 再生医療 2015 vol.33:267-272, 2015

金子新

臨床用iPS細胞バンキング
~CiRAにおける再生医療用HLAホモiPS細胞ストックプロジェクト
最新医学 69:724-733, 2014

南川敦隆、金子新

iPS細胞からの抗原特異的T細胞誘導とその臨床応用 血液フロンティア 24:201-207, 2014

金子新、辻浩一郎、山中伸弥

ヒトiPS細胞からの免疫細胞誘導とアレルギー疾患の治療・創薬 実験医学 31:2841-2846, 2013

金子新

iPS細胞を用いた免疫再生治療への挑戦 山梨医学 41:1-3, 2013

金子新、千葉滋

同種免疫反応の制御:GVHDに対する遺伝子治療 移植45:577-583, 2010

金子新(監訳)

ISSCR 幹細胞の臨床応用に関するガイドライン:2008年 国際幹細胞治療学会

金子新(監訳)

幹細胞治療について-患者ハンドブック:2008年 国際幹細胞治療学会

金子新、小野寺雅史、長澤俊郎

白血病に対する遺伝子治療 日本臨床63:637-40, 2005

金子新、中内啓光

造血幹細胞の可塑性 血液・腫瘍科 44:471-476, 2002

金子新、中内啓光

再生医学が分かる
第4章 組織幹細胞の可塑性と再生医学:2002年
羊土社

金子新、中内啓光

造血幹細胞の純化、分化、増殖 現代医療 32:2603-2608, 2000

金子新、小野寺雅史、中内啓光

造血細胞の遺伝子治療 組織培養工学 25:442-446, 1999

金子新、中内啓光

動員造血幹細胞の増殖と分化 血液・免疫・腫瘍4:49-55, 1999
go top